Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.

ABSTRACT: In patients hospitalized with COVID-19 pneumonia, both tocilizumab and baricitinib have been shown to have clinical benefit compared with placebo. To date, there are few data comparing the two treatments, and their relative benefits and harms are unknown. This study aims to evaluate the effectiveness of tocilizumab versus baricitinib in patients hospitalized with COVID-19 pneumonia and hypoxemia.

Design

Retrospective cohort study.

Setting

Seven inpatient acute-care hospitals in Wisconsin.

Participants

Patients hospitalized with COVID-19, hypoxemia, and Pao₂-to-Fio₂ ratio less than or equal to 300 mm Hg, who received either tocilizumab or baricitinib.

Interventions

Electronic chart review.

Measurements and main results

Patients were d

SUBMITTER: Roddy J 

PROVIDER: S-EPMC9243240 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature